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Image-Guided High-Dose Rate Intracavitary Brachytherapy in the Treatment of 
Medically Inoperable Early-Stage Endometrioid Type Endometrial Adenocarcinoma 
INTRODUCTION 
 In patients with multiple medical comorbidities which preclude 
surgical therapy for early stage endometrioid typ e endometrial cancer, 
radiotherapy is considered to be the only curative treatment.1 With the 
advent of iridium-192 high dose rate (HDR) brachytherapy, as well as 
more sophisticated three dimensional computed tomography (CT) and 
magnetic resonance imaging (MRI), HDR intracavitary brachytherapy 
dosimetry has become much more precise, allowing higher doses to be 
used for target tissues, with lower doses reaching surrounding structures, 
such as bladder and bowel.2 
 
CONCLUSIONS 
 Comorbid conditions are common in patients with low-grade, endometrioid type 
endometrial cancer. Most often, a combination of morbid obesity, diabetes, severe COPD, prior 
history of DVT with or without pulmonary embolism, and cardiac disease, which increase 
surgical risks, are also likely causes of premature death. In the event of inoperability due to the 
severity of these comorbid conditions, an unexpected late recurrence of endometrial cancer 
previously treated with radiotherapy is unlikely to be a significant driver of premature mortality 
when compared to the patient's other medical problems.  
 The Society recommends that the D90 for GTV should be at least 80 Gy, and that the D90 
for CTV be at least 48 Gy with intracavitary brachytherapy alone and at least 65 Gy when 
combined with EBRT.2 Our data demonstrate that at a dose lower than recommended (many of 
our patients were treated prior to these recommendations), treatment still has a high likelihood 
of success. 
 Our findings are consistent with other case series in the literature, though those studies 
included patients with higher grade disease and histologic subtypes other than endometrioid, 
and many used applicators other than tandem and ovoid.3-6 The dosimetry techniques used in 
this cohort demonstrate that lower radiotherapy doses to the CTV may provide similar efficacy 
to the ABS recommended minimum doses. The use of a single tandem in combination with EBRT 
allows greater flexibility in dose distribution without requiring the use of multiple applicators or 
dose delivery under general anesthesia. For patients unable to undergo surgical management of 
early-stage endometrioid endometrial cancer due to medical contraindications, treatment with 
intracavitary HDR brachytherapy is an excellent option for local disease control. 
 
METHODS 
 
 All American Joint Committee on Cancer (AJCC) stage T1a or T1b 
endometrioid type endometrial cancer, with medical comorbidities precluding 
surgical management treated at Temple University Hospital since 2010 were 
reviewed. Exclusion criteria were any evidence of nodal or cervical disease, or 
histologic types other than endometrioid.  
  All treatment planning utilized CT imaging following placement of HDR 
applicators (tandem with ring or tandem with ovoids). Prior to 2016, a high-risk 
clinical target volume was defined by the radiation oncologist as approximately 
2 cm myometrial depth. In 2016, a protocol was initiated where gross tumor 
volume (GTV) was defined as the width of the endometrial stripe as 
demonstrated by MRI. Clinical target volume (CTV) was defined as the entire 
uterine corpus, cervix, and proximal 4-5 cm of vaginal wall, excluding fibroids. 
Goal cumulative dose to 90 percent of the tissue volume (D90) in equivalent 2 
Gy fractions (EDQ2, α/ß=10) was 80-90 Gy for GTV and 60 Gy for CTV. 
 The decision to give external beam radiotherapy (EBRT) prior to 
brachytherapy was made on the basis of MRI-demonstrated myometrial 
invasion, indicating increased risk of occult pelvic nodal disease, or when it was 
thought that intracavitary brachytherapy alone would not deliver a sufficient 
dose to the entire CTV, most often in the setting of fibroids. 
To estimate the delivered doses given to the GTV and CTV in the patients who 
were dosed by the older protocol, isodose distributions were mapped onto the 
original treatment plans. GTV and CTV doses were calculated for each fraction 
of HDR brachytherapy. Equivalent dosage in 2 Gy fractions was calculated for 
each volume. Total dose to 2cm3 of bowel and bladder were also calculated 
using equivalent dose in 2 Gy fractions (α/ß= 3). Average follow-up time and 
survival were also calculated.  
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AIM 
To report the experience with high dose rate, image guided intracavitary 
brachytherapy in the treatment of medically inoperable, early stage 
endometrial cancer. 
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RESULTS 
 Eight patients received external beam 
radiation therapy (EBRT) followed by 
intracavitary HDR brachytherapy. Seven 
patients underwent intracavitary HDR 
brachytherapy alone. In all patients, mean 
cumulative dose to 90% (D90) of GTV was 
96.0 Gy (70.5-177.1) in equivalent dose in 2 
Gy fractions (EDQ2, α/ß=10). Mean 
cumulative D90 EDQ2 to CTV was 51.6 Gy 
(18.6-74).   
 Average follow-up was 29 months. Four 
patients died from concurrent disease(s) at 
an average of 2.83 years after completion of 
treatment. Except for one (6.6%) patient 
who recurred at 9 months following 
completion of treatment, all patients 
remained disease-free for the remainder 
of follow-up. Side effects were minimal, and 
included grade 1-2 diarrhea and dysuria 
most commonly.  
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Figure 1: Sample CT-
guided dose distribution 
plan with (clockwise from 
top left) transverse 
image, sagittal 
reconstruction, coronal 
reconstruction, and 3-D 
reconstruction. GTV is 
marked in red, CTV in 
light green, bowel in 
brown, and bladder in 
yellow. Isodose lines are 
also shown—
Red=160%, 
Orange=120%, and 
Yellow=100%. The 
transparent 100% 
isodose cloud 
encompassed most of 
CTV in 3D display. 
Figure 2: Dose volume histogram for the treatment plan in 
figure 1 to demonstrate 99% GTV coverage and 80% CTV 
coverage with the prescription dose of 1000 cGy while having 
relative low dose to the bladder and bowel (including rectum 
and sigmoid as well as small bowel labeled as recto-sigmoid) 
Treatment Avg D90 EDQ2 GTV  Avg D90 EDQ2 CTV D2cc EDQ2 Bowel D2cc EDQ2 
Bladder 
HDR ICBT 90.8 (73.8-121)  41.0 (18.6-66.6) 42.3 (31.1-52.3) 44.4 (34.7-53.6)  
HDR ICBT + 
EBRT 
100.5 (70.5-177.1) 60.9 (48.1-74) 68.0 (60.3-75.0)  63.1 (53.7-70.9) 
All patients 96.0 51.6 
Table 1: Average D90 EDQ2 to GTV and CTV, as well as D2cc EDQ2 to bladder and bowel in HDR ICBT alone 
and in combination with EBRT. Units: Gy.  Ranges shown in parentheses.  
